Worldwide Protein A Resin Industry (2019 to 2030) – Emerging Markets in the APAC Region Presents Lucrative Opportunities – ResearchAndMarkets.com

DUBLIN–()–The “Protein A Resin Market Research Report: By Source, Matrix, Application, End User – Industry Size, Share, Trends and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

The major protein A resin market drivers are the increasing geriatric population, prevalence of chronic diseases, funding for protein research, and need to meet the need for therapies for various conditions. The market revenue is projected to surge to $1,020.7 million by 2030, from $486.4 million in 2019, at a 7.0% CAGR during the forecast period (2019-2030). Protein A resin is used as a separation medium during purification processes, such immunoprecipitation and chromatography. It separates biochemical mixtures based on the enzyme-substrate, antigen-antibody, and receptor-nucleic acid interactions.

Companies Mentioned

  • Bio-Works Technologies AB
  • Amikozen Co. Ltd.
  • Bio-Rad Laboratories Inc.
  • Expedeon AG
  • Thermo Fisher Scientific Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Tosoh Corporation
  • Repligen Corporation
  • Novasep Holding SAS
  • Purolite Corporation
  • Kaneka Corporation
  • General Electric Company

Based on source, the protein A resin market is bifurcated into natural and recombinant, of which the recombinant bifurcation would display the higher CAGR, of 7.5%, during the forecast period. This is because recombinant protein A resins are heavily used during the production of monoclonal antibodies (mAb). Earlier, pharmaceutical companies did not pursue mAbs, owing to their stability, size, degradation rate, and delivery limitations. But, with increasing funding and focus of private and public institutions on protein-based research, the development of mAbs is picking up pace.

Across the world, the need for effective treatments for metabolic diseases, cardiovascular diseases, infectious diseases, and cancer is highly unmet. This is promoting the development of monoclonal antibodies, as they can function similar to the mediators involved in pathological processes. Additionally, mAbs and other therapeutic proteins are less toxic, highly effective and potent, safe, tolerable, selective, and chemically and biologically diverse, and they also do not accumulate much on tissues. Therefore, with the increase in the research and development (R&D) for mAbs, the usage of protein A resin would rise.

One of the primary reasons behind the rising demand for monoclonal antibodies is the increasing incidence of chronic diseases. mAbs display a suitable pharmacokinetic profile, their solubility can be customized, and they also have a lesser chance of inducing an immune response, which is essential for the treatment to work. The diseases caused by hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human papillomavirus (HPV) are increasing in prevalence, due to the low accessibility of healthcare in developing nations.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Introduction

4.1 Definition of Market Segments

4.1.1 By Source

4.1.2 By Matrix

4.1.3 By Application

4.1.4 By End User

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increasing number of collaborations and agreements

4.2.1.2 Evolution of the market with product launches

4.2.2 Drivers

4.2.2.1 Increasing research activities to address unmet medical needs in various therapeutic areas

4.2.2.2 Surging burden of chronic diseases

4.2.2.3 Rising investment and funding for protein-based research

4.2.2.4 Growing geriatric population

4.2.2.5 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Lack of updated regulatory standards

4.2.3.2 Contamination issues during protein A synthesis and high capital requirements for drug development

4.2.3.3 Complex nature of protein A chromatography process

4.2.3.4 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Emerging markets in the APAC region

4.3 Porter’s Five Forces Analysis

5. Global Market Size and Forecast

5.1 By Source

5.2 By Matrix

5.3 By Application

5.4 By End User

5.5 By Region

6. North America Market Size and Forecast

6.1 By Source

6.2 By Matrix

6.3 By Application

6.4 By End User

6.5 By Country

6.5.1 U.S. Market Size and Forecast

6.5.1.1 By source

6.5.1.2 By matrix

6.5.1.3 By application

6.5.1.4 By end user

6.5.2 Canada Market Size and Forecast

6.5.2.1 By source

6.5.2.2 By matrix

6.5.2.3 By application

6.5.2.4 By end user

7. Europe Market Size and Forecast

8. APAC Market Size and Forecast

9. LATAM Market Size and Forecast

10. MEA Market Size and Forecast

11. Competitive Landscape

11.1 Company Share Analysis

11.2 Product Benchmarking of Key Players

11.3 Strategic Developments of Key Players

11.3.1 Acquisitions

11.3.2 Collaboration

11.3.3 Other Developments

12. Company Profiles

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/kcfmbm.

Source

About the Author: Biotech Today

You might like